GENE FOR CURE SIGNED
Expanding and extending gene therapy of monogenic diseases of the haematopoietic system
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GENE FOR CURE project word cloud
Explore the words cloud of the GENE FOR CURE project. It provides you a very rough idea of what is the project "GENE FOR CURE" about.
Project "GENE FOR CURE" data sheet
The following table provides information about the project.
| Coordinator |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 2˙445˙267 € |
| EC max contribution | 2˙445˙267 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2015-AdG |
| Funding Scheme | ERC-ADG |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-10-01 to 2021-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR (PARIS) | coordinator | 2˙137˙827.00 |
| 2 | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS | FR (PARIS) | participant | 307˙440.00 |
Map
Project objective
Given that (i) not all patients with a monogenic disease affecting the lymphohaematopoietic system have an HLA-genoidentical sibling donor and (ii) severe immunological complications worsen the outcome in HLA-partially-matched hematopoietic stem cell transplantation (HSCT), the genetic modification of autologous hematopoietic stem cells (HSCs) has become a powerful curative treatment option for these individuals. The present project seeks to further consolidate the rationale for replacing HLA-partially-matched HSCT with a gene therapy approach. Wiskott-Aldrich syndrome is a primary immunodeficiency whose severity is due to impairment of both lymphoid and myeloid cell function. We have reported robust evidence showing that the infusion of gene-corrected autologous HSCs enables the restoration of the T cell function. However, we are still cautious with regard to claiming the stable correction of autoimmunity and thrombocytopenia. Accordingly, we plan to thoroughly monitor long-term B cell functional outcomes and the platelet count in our treated patients. Moreover, we wish to extend the gene therapy approach to the SCID caused by mutations in the DLREIC gene, since the long-term post-HSCT outcomes are particularly poor. The preclinical work has been completed; initiation of a clinical protocol is the next step. Immune-dysregulation polyendocrinopathy enteropathy X-linked (IPEX) and sickle cell anaemia (SCA) are the last two target diseases. IPEX is a devastating disease caused by mutation of FOXP3 transcription factor; it may be possible to correct it by infusing gene-modified CD4Tcells. We intend to accumulate the data required to prove our working hypothesis. SCA is a worldwide public health issue. We are seeking to improve the conventional gene therapy procedure and to evaluate the efficacy of CrisP/Cas9-mediated disruption of the CIS-regulatory elements required for HbF silencing. This disruption may provide a cure for SCA.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Leslie Weber, Valentina Poletti, Elisa Magrin, Chiara Antoniani, Samia Martin, Charles Bayard, Hanem Sadek, Tristan Felix, Vasco Meneghini, Michael N. Antoniou, Wassim El-Nemer, Fulvio Mavilio, Marina Cavazzana, Isabelle Andre-Schmutz, Annarita Miccio An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype published pages: 268-280, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2018.07.012 |
Molecular Therapy - Methods & Clinical Development 10 | 2020-02-19 |
| 2018 |
Chiara Antoniani, Vasco Meneghini, Annalisa Lattanzi, Tristan Felix, Oriana Romano, Elisa Magrin, Leslie Weber, Giulia Pavani, Sara El Hoss, Ryo Kurita, Yukio Nakamura, Thomas J. Cradick, Ante S. Lundberg, Matthew Porteus, Mario Amendola, Wassim El Nemer, Marina Cavazzana, Fulvio Mavilio, Annarita Miccio Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus published pages: 1960-1973, ISSN: 0006-4971, DOI: 10.1182/blood-2017-10-811505 |
Blood 131/17 | 2020-02-19 |
| 2017 |
Marina Cavazzana, Chiara Antoniani, Annarita Miccio Gene Therapy for β-Hemoglobinopathies published pages: 1142-1154, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.03.024 |
Molecular Therapy 25/5 | 2020-02-19 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GENE FOR CURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GENE FOR CURE" are provided by the European Opendata Portal: CORDIS opendata.